DKTK-Studienregister

DetailsucheDetailsuche
Klicken Sie auf Detailsuche, um z.B. nach Therapielinie, molekularem Marker oder Rekrutierungsstatus zu suchen.
FreitextsucheFreitextsuche
Sie können hier nach dem Studienkurzcode oder einem Teil des Studientitels suchen.
Studienauswahl
Zentren
Status der Studie

» Solide Tumore und Neoplasien » Verschiedene solide Tumore/Neoplasien

Alle Linien

AMG 510_20170543
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreak 100) (Aktiv)

ATRi_Bay–Studie
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug (Aktiv)

BI 907828
This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors) (Aktiv)

BNT411-01
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 (Aktiv)

CMCS110Z2102
A Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (Aktiv)

CONKO-011
Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients (Aktiv)

CPDR001X2X01B
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments (Aktiv)

LIBERAL
Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients (Aktiv)

LIBRETTO-201
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation (Aktiv)

MAESTRO
Magnetic Resonance-guided Adaptive Stereotactic Body Radiotherapy for Hepatic Metastases (Aktiv)

MASTERKEY-318
This is a phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec injected intrahepatically into liver tumors with known progression alone and in combination with systemic IV administration of pembrolizumab, in subjects with non-HCC liver metastases from BC, CRC, GEC, melanoma, NSCLC, RCC, and subjects with HCC. (Aktiv)

MK-3475-587
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (Aktiv)

MR Linac
Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac (Aktiv)

Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors
Master Protocol to Assess the Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors (Aktiv)

NEPO_MUC
Neoadjuvante Strahlentherapie (N-RT) zur Behandlung von intrazerebalen Metastasen solider Tumore (Aktiv)

RESMAIN Studie
hase II Trial to Evaluate Resminostat for Maintenance Treatment (Aktiv)

ROSETTA
RandOmized Study Exploring the Combination of radioTherapy With Two Types of Acupuncture Treatment: The ROSETTA Trial (ROSETTA) (Aktiv)

SPIN-MET, SPIME2013
Efficacy of Dose Intensified Radiotherapy of Spinal Metastases by Hypofractionated Radiation and IGRT hfSRT Mediated Boost (SPIN-MET) (Aktiv)

STARTRK-2
Studie der Phase II zu Entrectinib bei Patienten soliden Tumoren, die ein NTRK1/2/3-, ROS1- oder ALK-Gen-Rearrangement aufweisen (Aktiv)

STEREOBRAIN
Whole-brain radiotherapy (WBRT) versus stereotactic radiosurgery (SRS) in patients with 4 - 10 brain metastases. A phase II prospective monocentric study (Aktiv)

SanofiTED15297
A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors (Aktiv)

SenPET
Study to Assess Safety and PET Imaging Characteristics of a Novel Senescence-specific Radiotracer [18F]FPyGal (2-[Fluorine-18]Fluoro-3-pyridinyl-β-D-galactopyranoside) (Aktiv)

Erstlinie

Keynote-158, MK3475-158
Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (Aktiv)

LCNEC-ALPINE
A Phase II, single-arm trial of addition of Atezolizumab to standard chemotherapy of Platinum and Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung (Aktiv)

TREASURE
Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease (Aktiv)

Zweitlinie oder später

1432-0001
A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) (Aktiv)

Amgen 20190136 / ECTU - IM1 - IM3
Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (Aktiv)

BMS CA224-020
The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or cannot be removed by surgery. (Aktiv)

BNT211-01
A Trial to Evaluate the Safety and Efficacy of CLDN6 CAR-T +/- CLDN6 RNA-LPX (Aktiv)

Basilea
Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma (Aktiv)

Bayer AhRi BAY 2416964
A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer (Aktiv)

BoB Module 1
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (Aktiv)

CA030-001
An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread (Aktiv)

CB103-C-101
Phase I/II Studie zu CB-103 bei fortgeschrittenen Krebserkrankungen (Aktiv)

CDI-CS-002
Phase 1/2a Studie zu BAL101553 als Zweitlinientherapie bei rezidivierenden/progressiven Hirntumoren (Aktiv)

CHORDOM (HIT-1 / CH.P.12C)
Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base (HIT-1) (Aktiv)

CINC280A2X02B
Study to allow patients with cMET-dependent malignancies to continue capmatinib treatment as monotherapy or in combination treatment (Aktiv)

CLDK378A2407
study of ceritinib in patients with advanced solid tumors and hematological malignancies characterized by genetic abnormalities of ALK (Aktiv)

CNIR178X2201
Study of efficacy and safety of NIR178 and PDR001 combination in patients with selected solid tumors and non-Hodgkin lymphoma (Aktiv)

CNIZ985B1201
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab (Aktiv)

CRAFT Studie (PMO-1602)
The NCT-PMO-1602 Phase II Trial (Aktiv)

CatalYm CTL-002-001
First-in-Human Study of the GDF-15 Neutralizing Antibody CTL-002 in Patients With Advanced Cancer (GDFATHER) (Aktiv)

CheckMate 848
Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Advanced or Metastatic Solid Tumors (Aktiv)

DLL3
A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for Delta-Like Ligand 3 (DLL3). (Aktiv)

GO29665
Study of The Safety And Pharmacokinetics of Cobimetinib (Aktiv)

GO39733
This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of RO7198457 as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 [anti-PD-L1] antibody). (Aktiv)

I3Y-MC-JPCS Abemaciclib
A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors (Aktiv)

IMA 201-101
TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) (Aktiv)

IMA 401-101
A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER®), in Patients With Recurrent and/or Refractory Solid Tumors. (Aktiv)

INCB 54828-207
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) (Aktiv)

INFORM2-NivEnt (NCT-2017-0516)
INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (Aktiv)

INSIGHT
Phase I study to evaluate the feasibility and safety of IMP321 in solid tumors (Aktiv)

IRON-2
Radiotherapy With Integrated-boost in Patients With Spinal Bone Metastases (Aktiv)

Imcheck ICT01-101 (EVICTION)
First-in-Human Study of ICT01 in Patients With Advanced Cancer (Aktiv)

Immatics IMA 202-101
TCR-engineered T Cells in Solid Tumors Including NSCLC and HCC Patients (ACTengine) (Aktiv)

Immatics IMA 203-101
TCR-engineered T Cells in Solid Tumors (Aktiv)

LIBRETTO-001
Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (Aktiv)

LOXO-TRK-15002
Phase II, multi-center, open-label study of patients with advanced solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3. (Aktiv)

LOXO-TRK-15003
A Phase 1/2 Clinical Trial of Pediatric Cancer Patients With Solid Tumors Treated with LOXO-101 (Aktiv)

MAK683
Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies (Aktiv)

MCLA-128-CL01/MERUS
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (Aktiv)

MK-3475
Study of Pembrolizumab (MK-3475) in Children (Aktiv)

MK-7339-007
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (Aktiv)

MSD V937-013
Phase 1b/2 Study of V937 Injected into Tumors in Combination with Intravenous (IV) Pembrolizumab (Aktiv)

NCT-2017-0417
Evaluation of the efficacy of the combination of olaparib and trabectedin in adult patients with locally advanced/metastatic solid tumors that failed standard treatment and whose molecular sequencing tumor profiles show homologous recombination repair (HRR) defects. The primary objective is to show superior disease control rate in patients with HRR-deficient tumors treated with olaparib and trabectedin compared to treatment according to current guidelines (physician's choice) (Aktiv)

NOTCH CB-103-C-101
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies (Aktiv)

Novartis CDKY709A12101C
This is a phase I/Ib, open label study. The escalation portion will characterize the safety and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior anti-PD-1/PD-L1 therapy, or subjects with NPC (Aktiv)

PH-IL12L19L19-01/19 -Dodekin
Safety and Early Signs of Efficacy of IL12-L19L19. (Aktiv)

PMO-1601
CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma (NCT-PMO-1601) (Aktiv)

Pekannuss
Trial Comparing Parenteral Nutrition (PN) Using Eurotubes® vs. 2/3-chamber Bags in Subjects With Solid Tumors Requiring PN (PEKANNUSS) (Aktiv)

Proto-R-Kinder
Protonentherapie bei Kindern: Prospektive Erfassung von Effizienz und Nebenwirkungen bei klinischen Standarddosen (Aktiv)

RAGNAR
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (Aktiv)

SATURNUS
Hypofractionated stereotactic radiotherapy versus single fraction stereotactic radiotherapy to the resection cavity of brain metastases after surgical resection. (Aktiv)

SOLID_MGA012-01
A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors (Aktiv)

SORATRAM
Multizentrische Basket-Studie zur kombinierten CRAF- und MEK-Inhibition bei fortgeschrittenen Tumorerkrankungen mit BRAF-Mutationen und eingeschränkter Kinase-Aktivität (Aktiv)

STARTRK-NG
A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (Aktiv)

STARVATION
Short-term Starvation vs. Normal Diet before Chemotherapy of Solid Tumors (Aktiv)

VB N-02
Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors (Aktiv)

DKTK-Studienregister
Dr. N. Gökbuget, Dipl.-Biol. K. Ihrig | Ohne Gewähr für Richtigkeit oder Vollständigkeit | ccp@dkfz.de